These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 7512087)
41. Prognosis and cytomorphometry in breast cancer. Kuenen-Boumeester V; Van Putten WL; Blonk DI; Boon M Eur J Cancer Clin Oncol; 1987 Jan; 23(1):107-8. PubMed ID: 3595681 [No Abstract] [Full Text] [Related]
42. Breast size and cancer. Robertson AJ; Clark J; Hall AW; Swanson Beck J; Cuschieri A Br Med J; 1977 May; 1(6071):1283. PubMed ID: 861575 [No Abstract] [Full Text] [Related]
43. [Pathologic histology as contribution to prognosis of breast cancer]. BRACHETTO-BRIAN D Prensa Med Argent; 1951 Mar; 38(12):690-2. PubMed ID: 14834063 [No Abstract] [Full Text] [Related]
44. Tracing the evolutionary history of breast cancer. Koh J; Im SA Nat Rev Cancer; 2024 Oct; 24(10):653. PubMed ID: 39143176 [No Abstract] [Full Text] [Related]
45. Biologic variability of breast carcinoma in relation to diagnosis and therapy. BLACK MM; SPEER FD N Y State J Med; 1953 Jul; 53(13):1560-3. PubMed ID: 13072832 [No Abstract] [Full Text] [Related]
46. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100 [TBL] [Abstract][Full Text] [Related]
47. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. el-A Helal T; Khalifa A; Kamel AS Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168 [TBL] [Abstract][Full Text] [Related]
49. Clinical relevance of breast cancer biology. Oza AM; Tannock IF Hematol Oncol Clin North Am; 1994 Feb; 8(1):1-14. PubMed ID: 7512087 [TBL] [Abstract][Full Text] [Related]
50. Biomarkers for breast cancer. Beenken SW; Bland KI Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573 [TBL] [Abstract][Full Text] [Related]
51. [Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast]. Puglisi F; Di Loreto C; Beltrami CA Ann Ital Chir; 1999; 70(3):335-41. PubMed ID: 10466235 [TBL] [Abstract][Full Text] [Related]
52. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Huber KE; Carey LA; Wazer DE Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684 [TBL] [Abstract][Full Text] [Related]